Anthem Inc. is committed to playing an active role in identifying best approaches to health and care management. As part of that belief, Anthem's outcomes research subsidiary, HealthCore Inc., will begin reaching out to select members of Anthem affiliated health plans regarding an opportunity to participate in an innovative research study on heart disease. The study is currently underway to help determine the most effective and safest dose of aspirin to prevent heart attacks and strokes, and Anthem's affiliated health plans are expected to play a significant role in recruitment. This landmark study, called ADAPTABLE, involves more than 30 leading health and medical organizations across the U.S. with a goal of enrolling 15,000 participants. The study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI), will compare regular strength aspirin (325mg) to baby aspirin (81mg) among people with heart disease to help determine the best dose to use. While aspirin is widely prescribed to prevent strokes and heart attacks in people living with heart disease, the right dose is not established. This is because one dose may be better at preventing heart attacks while another may prevent serious side effects, such as bleeding. Heart disease causes one in four deaths in the U.S., making it the country's leading killer, and heart disease places enormous burdens on patients and their families as well as the U.S. healthcare system. While the ADAPTABLE trial is important on its own, it’s also the first study to be conducted through PCORnet, the National Patient-Centered Clinical Research Network. This innovative PCORI initiative is designed to empower people to make informed healthcare decisions by enabling clinical research that is faster, easier, less costly and, most importantly more relevant to their needs.